A carregar...

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

PURPOSE: HER2-amplified breast cancer is sometimes clinically insensitive to HER2 targeted treatment with trastuzumab. Laboratory models of resistance have causally implicated changes in HER2 expression and activation of the PI3K-AKT pathway. We conducted a prospective tissue acquisition study to de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chandarlapaty, Sarat, Sakr, Rita A., Giri, Dilip, Patil, Sujata, Heguy, Adriana, Morrow, Monica, Modi, Shanu, Norton, Larry, Rosen, Neal, Hudis, Clifford, King, Tari A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3525734/
https://ncbi.nlm.nih.gov/pubmed/23092874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-1785
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!